Endostatin Combined with Platinum-Based Chemo-radiotherapy for Advanced Non-small Cell Lung Cancer

Cell Biochemistry and Biophysics

Volumn 71, Issue 2, 2015, Pages 571-577

  Jiang, Xuan ^a   Guan, Wei ^a   Li, Mengxia ^a   Liang, Wei ^a   Qing, Yi ^a   Dai, Nan ^a   Zhang, Shiheng ^a   Deng, Yi ^a   Meng, Hao ^a   Yang, Yuxin ^a   Zhong, Zhaoyang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Advanced non small cell lung cancer; Arterial infusion; Endostatin; Recombinant human endostatin

Indexed keywords

ANTINEOPLASTIC AGENT; ENDOSTATIN; PLATINUM COMPLEX;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CLINICAL TRIAL; FEMALE; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; ENDOSTATINS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS;

EID: 84922577509     PISSN: 10859195     EISSN: 15590283     Source Type: Journal    
DOI: 10.1007/s12013-014-0236-6     Document Type: Article

References (23)

1. Jemal, A., et al. (2011). Global cancer statistics. CA: A Cancer Journal for Clinicians,61(2), 69–90.
2. Govindan, R., Page, N., Morgensztern, D., Read, W., Tierney, R., Vlahiotis, A., et al. (2006). Changing epidemiology of small cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. Journal of Clinical Oncology,24, 4539–4544.
3. Howlader, N., Noone, A. M., Krapcho, M., Garshell, J., Neyman, N., Altekruse, S. F., Kosary, C.L., Yu, M., Ruhl, J., Tatalovich, Z., Cho, H., Mariotto, A., Lewis, D. R., Chen, H. S., Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.
4. Novello, S., & Le Chevalier, T. (2003). Chemotherapy for non-small-cell lung cancer. Part 1: Early-stage disease. Oncology (Williston Park),17(3), 357–364.
5. Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., et al. (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New England Journal of Medicine,346, 92–98.
6. Jain, R. K. (2001). Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nature Medicine,7(9), 987–989.
7. O’Reilly, Michael S., et al. (1997). Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell,88, 277–285.
8. Rong, B., et al. (2012). Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World Journal of Surgical Oncology,10, 170.
9. Ge, Wei, et al. (2011). Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: A meta-analysis. Asian Pacific Journal of Cancer Prevention,12, 2901–2907.
10. Dawar, S., et al. (2013). Multifunctional and multitargeted nanoparticles for drug delivery to overcome barriers of drug resistance in human cancers. Drug Discovery Today,18(23–24), 1292–1300.
11. Bhattacharya, A., Seshadri, M., Oven, S. D., Toth, K., Vaughan, M. M., & Rustum, Y. M. (2008). Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs. Clinical Cancer Research,14(12), 3926–3932. doi:10.1158/1078-0432.CCR-08-0212.
12. Malonne, Hugues, et al. (1999). Mechanisms of tumor angiogenesis and therapeutic implications: Angiogenesis inhibitors. Clincal and Experimental Metastasis,17, 1–14.
13. Zhang, S., Meng, Q., & Zhang, J. (2012). Analysis of bronchial artery interventional therapy for middle or late stage central lung cancer. Chinese Journal of Clinicians,6(16), 4879–4881.
14. Zhong, Z., et al. (1019). Recombinant human endostatin combined with definitive chemoradiotherapy as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma of the oesophagus. British Journal of Radiology,2012(85), 1104–1109.
15. Wu, H., et al. (2010). The inhibitory effects of rh-endostatin (YH-16) in combination with radiotherapy on lung adenocarcinoma A549 in mice and the underlying mechanisms. Journal of Huazhong University of Science and Technology,30(1), 108–112.
16. Nakanishi, M., Yoshida, Y., & Natazuka, T. (2012). Prospective study of transarterial infusion of docetaxel and cisplatin to treat non-small-cell lung cancer in patients contraindicated for standard chemotherapy. Lung Cancer,77(2), 353–358.
17. Adbollahi, Amir, et al. (2004). Endostatin’s antiangiogenic signaling network. Molecular Cell,13, 649–663.
18. Folkman, J. (2006). Antiangiogenesis in cancer therapy: Endostatin and its mechanisms of action. Experimental Cell Research,312(5), 594–607.
19. Nagata, Y., et al. (2000). Neoadjuvant chemotherapy by transcatheter arterial infusion method for uterine cervical cancer. Journal of Vascular and Interventional Radiology,11(3), 313–319.
20. Patt, Yehuda Z., et al. (1980). Percutaneous hepatic arterial infusion (HAI) of mitomycin C and floxuridin (FUDR): An effective treatment for metastatic colorectal carcinoma in the liver. Cancer,46, 261–265.
21. Ferrara, N., & Kerbel, R. S. (2005). Angiogenesis as a therapeutic target. Nature,438(7070), 967–974.
22. Jain, R. K. (2001). Delivery of molecular and cellular medicine to solid tumors. Advanced Drug Delivery Reviews,46, 149–168.
23. Tsimberidou, A.-M., Giles, F. J., Khouri, I., Bueso-Ramos, C., Pilat, S., Thomas, D. A., et al. (2005). Low-dose interleukin-11 in patients with bone marrow failure: Update of the M.D. Anderson Cancer Center experience. Annals of Oncology,16(1), 139–145.